KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Invested Capital (2018 - 2025)

Historic Invested Capital for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $477.1 million.

  • Castle Biosciences' Invested Capital rose 576.96% to $477.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.1 million, marking a year-over-year increase of 576.96%. This contributed to the annual value of $465.9 million for FY2024, which is 1906.34% up from last year.
  • Per Castle Biosciences' latest filing, its Invested Capital stood at $477.1 million for Q3 2025, which was up 576.96% from $465.4 million recorded in Q2 2025.
  • Castle Biosciences' Invested Capital's 5-year high stood at $477.1 million during Q3 2025, with a 5-year trough of $378.8 million in Q2 2023.
  • For the 5-year period, Castle Biosciences' Invested Capital averaged around $421.3 million, with its median value being $415.9 million (2021).
  • As far as peak fluctuations go, Castle Biosciences' Invested Capital skyrocketed by 26951.54% in 2021, and later tumbled by 1017.22% in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Invested Capital stood at $411.7 million in 2021, then dropped by 3.06% to $399.2 million in 2022, then fell by 1.97% to $391.3 million in 2023, then increased by 19.06% to $465.9 million in 2024, then increased by 2.41% to $477.1 million in 2025.
  • Its Invested Capital stands at $477.1 million for Q3 2025, versus $465.4 million for Q2 2025 and $450.3 million for Q1 2025.